BACKGROUND: We compare the effect of 4 different antiretroviral regimens on limb and visceral fat. METHODS:A5224s was a substudy of A5202, a trial of human immunodeficiency virus type 1 (HIV-1)-infected, treatment-naive subjects randomized toblinded abacavir-lamivudine (ABC-3TC) or tenofovir DF-emtricitabine (TDF-FTC) with open-label efavirenz (EFV) or atazanavir-ritonavir (ATV-r). The primary endpoint was the presence of lipoatrophy (≥ 10% loss of limb fat) at week 96 by intent-to-treat (ITT) analysis. Secondary endpoints included changes in limb and visceral fat. Statistical tests included linear regression, binomial, two-sample t test, and Fisher's exact test. RESULTS:A5224s enrolled 269 subjects; 85% were male, and 47% were white non-Hispanic. The subjects had a median baseline HIV-1 RNA level of 4.6 log(10) copies/mL, a median age of 38 years, a median CD4+ cell count of 233 cells/μL, median limb fat of 7.4 kg, median visceral adipose tissue (VAT) of 84.1 cm(2), and VAT: total adipose tissue (TAT) ratio of 0.31. At week 96, estimated prevalence of lipoatrophy (upper 95% confidence interval [CI]) was 18% (25%) for ABC-3TC and 15% (22%) for TDF-FTC (P = .70); this was not significantly less than the hypothesized 15% for both (P ≥ .55 for both). The secondary as-treated (AT) analysis showed similar results. At week 96, the estimated mean percentage change from baseline in VAT was higher for the ATV-r group than for the EFV group (26.6% vs 12.4%; P = .090 in ITT analysis and 30.0% vs 14.5%; P = .10 in AT analysis); however, the percentage change in VAT:TAT was similar by ITT and AT analysis (P ≥ .60 for both). Results were similar for absolute changes in VAT and VAT:TAT. CONCLUSIONS:ABC-3TC- and TDF-FTC-based regimens increased limb and visceral fat at week 96, with a similar prevalence of lipoatrophy. Compared to the EFV group, subjects assigned to ATV-r had a trend towards higher mean percentage increase in VAT. CLINICAL TRIALS REGISTRATION: NCT00118898.
RCT Entities:
BACKGROUND: We compare the effect of 4 different antiretroviral regimens on limb and visceral fat. METHODS: A5224s was a substudy of A5202, a trial of human immunodeficiency virus type 1 (HIV-1)-infected, treatment-naive subjects randomized to blinded abacavir-lamivudine (ABC-3TC) or tenofovir DF-emtricitabine (TDF-FTC) with open-label efavirenz (EFV) or atazanavir-ritonavir (ATV-r). The primary endpoint was the presence of lipoatrophy (≥ 10% loss of limb fat) at week 96 by intent-to-treat (ITT) analysis. Secondary endpoints included changes in limb and visceral fat. Statistical tests included linear regression, binomial, two-sample t test, and Fisher's exact test. RESULTS: A5224s enrolled 269 subjects; 85% were male, and 47% were white non-Hispanic. The subjects had a median baseline HIV-1 RNA level of 4.6 log(10) copies/mL, a median age of 38 years, a median CD4+ cell count of 233 cells/μL, median limb fat of 7.4 kg, median visceral adipose tissue (VAT) of 84.1 cm(2), and VAT: total adipose tissue (TAT) ratio of 0.31. At week 96, estimated prevalence of lipoatrophy (upper 95% confidence interval [CI]) was 18% (25%) for ABC-3TC and 15% (22%) for TDF-FTC (P = .70); this was not significantly less than the hypothesized 15% for both (P ≥ .55 for both). The secondary as-treated (AT) analysis showed similar results. At week 96, the estimated mean percentage change from baseline in VAT was higher for the ATV-r group than for the EFV group (26.6% vs 12.4%; P = .090 in ITT analysis and 30.0% vs 14.5%; P = .10 in AT analysis); however, the percentage change in VAT:TAT was similar by ITT and AT analysis (P ≥ .60 for both). Results were similar for absolute changes in VAT and VAT:TAT. CONCLUSIONS: ABC-3TC- and TDF-FTC-based regimens increased limb and visceral fat at week 96, with a similar prevalence of lipoatrophy. Compared to the EFV group, subjects assigned to ATV-r had a trend towards higher mean percentage increase in VAT. CLINICAL TRIALS REGISTRATION: NCT00118898.
Authors: Daniel Podzamczer; Elena Ferrer; Esteban Martínez; Luis Del Rio; Joaquín Rosales; Jordi Curto; Esteban Ribera; Pilar Barrufet; Josep M Llibre; Miquel Aranda Journal: AIDS Res Hum Retroviruses Date: 2009-06 Impact factor: 2.205
Authors: Michael P Dubé; Robert A Parker; Pablo Tebas; Steven K Grinspoon; Robert A Zackin; Gregory K Robbins; Ronenn Roubenoff; Robert W Shafer; David A Wininger; William A Meyer; Sally W Snyder; Kathleen Mulligan Journal: AIDS Date: 2005-11-04 Impact factor: 4.177
Authors: Paul E Sax; Camlin Tierney; Ann C Collier; Margaret A Fischl; Katie Mollan; Lynne Peeples; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Susan L Koletar; Victoria A Johnson; P Jan Geiseler; Eric S Daar Journal: N Engl J Med Date: 2009-12-01 Impact factor: 91.245
Authors: Michael P Dubé; Lauren Komarow; Kathleen Mulligan; Steven K Grinspoon; Robert A Parker; Gregory K Robbins; Ronenn Roubenoff; Pablo Tebas Journal: J Acquir Immune Defic Syndr Date: 2007-08-15 Impact factor: 3.731
Authors: Richard H Haubrich; Sharon A Riddler; A Gregory DiRienzo; Lauren Komarow; William G Powderly; Karin Klingman; Kevin W Garren; David L Butcher; James F Rooney; David W Haas; John W Mellors; Diane V Havlir Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Stephane De Wit; Caroline A Sabin; Rainer Weber; Signe Westring Worm; Peter Reiss; Charles Cazanave; Wafaa El-Sadr; Antonella d'Arminio Monforte; Eric Fontas; Matthew G Law; Nina Friis-Møller; Andrew Phillips Journal: Diabetes Care Date: 2008-02-11 Impact factor: 17.152
Authors: Kristine M Erlandson; Suzanne P Fiorillo; Sandra Wagner Cardoso; Cynthia Riviere; Jorge Sanchez; James Hakim; Nagalingeswaran Kumarasamy; Sharlaa Badal-Faesen; Umesh Lalloo; Johnstone Kumwenda; Thomas B Campbell; Todd T Brown Journal: AIDS Res Hum Retroviruses Date: 2017-05-16 Impact factor: 2.205
Authors: Kristine M Erlandson; Douglas Kitch; Camlin Tierney; Paul E Sax; Eric S Daar; Pablo Tebas; Kathleen Melbourne; Belinda Ha; Nasreen C Jahed; Grace A McComsey Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Grace A McComsey; Douglas Kitch; Paul E Sax; Camlin Tierney; Nasreen C Jahed; Kathleen Melbourne; Belinda Ha; Todd T Brown; Anthony Bloom; Neal Fedarko; Eric S Daar Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Cindy J Bednasz; Charles S Venuto; Qing Ma; Eric S Daar; Paul E Sax; Margaret A Fischl; Ann C Collier; Kimberly Y Smith; Camlin Tierney; Edward P Acosta; Donald E Mager; Gene D Morse Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191
Authors: Philip M Grant; Douglas Kitch; Grace A McComsey; Ann C Collier; Benedetta Bartali; Susan L Koletar; Kristine M Erlandson; Jordan E Lake; Michael T Yin; Kathy Melbourne; Belinda Ha; Todd T Brown Journal: AIDS Date: 2016-11-28 Impact factor: 4.177